PharmacoEconomics & Outcomes News

February 2019, Volume 821, Issue 1, pp 8–8 | Cite as

Avelumab promising cost-effective option for Merkel cell carcinoma

Clinical study

First Online: 09 February 2019

This is a preview of subscription content, log in to check access.

Reference

1. Bullement A, et al. Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. PharmacoEconomics-Open : 24 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-018-0115-y

Copyright information

© Springer Nature Switzerland AG 2019